Company Overview of Apotex Inc.
Apotex Inc., a pharmaceutical company, engages in the research and development, manufacture, distribution, and sale of generic pharmaceuticals in Canada and internationally. It offers medicines in various dosage forms. The company serves patients, healthcare providers, payers, and governments. It offers its products through pharmacies and healthcare facilities. The company was founded in 1974 and is based in Toronto, Canada with additional offices in Saudi Arabia. It has facilities in Montreal, Richmond Hill, Toronto, Etobicoke, Mississauga, Brantford, Windsor, Winnipeg, London, Calgary, and Vancouver, Canada; and subsidiaries, joint ventures, and licensing agreements in Australia, Belgium, ...
150 Signet Drive
Toronto, ON M9L 1T9
Founded in 1974
Key Executives for Apotex Inc.
Chief Executive Officer and President
Founder and Chairman of the Board
President of Apotex International
Director of Research and Development
Director of Marketing -Canada
Compensation as of Fiscal Year 2014.
Apotex Inc. Key Developments
Apotex Inc. Announces Management Appointments
Aug 26 14
Apotex Inc. announced the appointments of Dr. Jeremy B. Desai to President and C.E.O. effective August 1, 2014 and Mr. Jack Kay, the former CEO of Apotex to the position of Vice Chairman of the Board effective the same date. Dr. Desai has been at Apotex for the last 11 years in different roles, including EVP and Global Head of R&D and most recently as President and Chief Operating Officer. He takes over the helm of Apotex at a great time of change in the industry and the healthcare system.
Mylan Inc. Wins Motion for Temporary Restraining Order Against Apotex Inc. and Apotex Corporation
Jul 23 14
Mylan Inc. announced that the U.S. District Court for the District of New Jersey granted its motion for a temporary restraining order against Apotex Inc. and Apotex Corporation in litigation relating to Paroxetine CR, the authorized generic of GlaxoSmithKline's Paxil(R) CR. The District Court ordered Apotex to immediately discontinue all sales and supply of Paroxetine CR. Mylan previously obtained an order enjoining GlaxoSmithKline from supplying Paroxetine CR to Apotex. In addition, the District Court ordered Apotex to immediately recall all product from its direct customers that was shipped since the injunction was entered on July 16, 2014. Mylan has an exclusive license to an Orange Book patent pertaining to Paxil CR which expires in July 2016, with pediatric exclusivity extending until Jan. 19, 2017.
Pfizer Inc. Appeal Court Decision Regarding Celebrex Reissue Patent Against Teva Pharmaceuticals USA, Inc., Mylan Pharmaceuticals Inc., Watson Laboratories, Inc., Lupin Pharmaceuticals, USA, Inc., Apotex Corp., and Apotex, Inc
Mar 12 14
Pfizer Inc. confirmed that the United States District Court for the Eastern District of Virginia granted summary judgment invalidating the reissue patent (U.S. Patent No. RE44,048), covering methods of treating osteoarthritis and other approved conditions with celecoxib, the active ingredient in Celebrex(R). Pfizer disagrees with the ruling and will pursue all available remedies, including an immediate appeal of the court's decision. A trial was scheduled to begin on March 19, 2014, for infringement of the reissue patent in the action brought by Pfizer against the generic companies Teva Pharmaceuticals USA, Inc., Mylan Pharmaceuticals Inc., Watson Laboratories, Inc., Lupin Pharmaceuticals, USA, Inc., Apotex Corp., and Apotex, Inc. Each of these generic companies previously filed an abbreviated new drug application with the United States Food and Drug Administration seeking approval to market a generic form of celecoxib in the United States beginning on May 30, 2014, when Pfizer's basic Celebrex(R) compound patent (including the six-month pediatric exclusivity period) expires. This is eighteen months prior to the December 2, 2015 expiration (including the six-month pediatric exclusivity period) of the reissue patent.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 11, 2013